Journal: Frontiers in Immunology

Article Title: YiQi-HuoXue prescription ameliorates LPS-induced sepsis-associated encephalopathy via VCAM-1–mediated microglial efferocytosis

doi: 10.3389/fimmu.2026.1792688

Figure Lengend Snippet: Pharmacological modulation of MERTK and VCAM1 implicates a VCAM1-linked efferocytosis and anti-inflammatory mechanism for YQHXP. (A) Flow cytometry analysis of PKH67 + /F4/80 + double-positive cells in BV2–HT22 co-culture across seven groups. (B) Quantification of efferocytosis rate(n=3). (C) Flow cytometry plots of apoptotic BV2 cells (Annexin V/PI staining). (D) Quantification of apoptosis rate(n=3). (E) Western blot and quantification of C1QB protein expression(n=3). (F) Western blot and quantification of MERTK protein expression(n=3). (G) Western blot and quantification of VCAM1 protein expression(n=3). (H) TNF-α levels in BV2 supernatant measured by ELISA(n=3). IL-6 levels in BV2 supernatant measured by ELISA(n=3). *P < 0.05 relative to the model group; **P < 0.01, ***P < 0.001 relative to the model group. # P < 0.05 relative to the UNC2250 group; ## P < 0.01 relative to the UNC2250 group; ### P < 0.001 relative to the UNC2250 group.

Article Snippet: The MERTK inhibitor UNC2250 (Cat. HY-15797), rutin (Cat. HY-N0148), and Ginsenoside Rg1 (Cat. HY-N0045) were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Flow Cytometry, Co-Culture Assay, Staining, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia

doi: 10.1186/s13046-026-03657-y

Figure Lengend Snippet: The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE and monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated

Article Snippet: Mouse IgG1/kappa light chain MERTK-specific monoclonal antibodies were generated in mice by immunization with Fc-tagged human MERTK peptide (R&D Systems, Minneapolis, MN) USA).

Techniques: Activity Assay, Expressing, Staining, Flow Cytometry

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia

doi: 10.1186/s13046-026-03657-y

Figure Lengend Snippet: The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML primary cells. A - D Bar graphs show the percentage of relative luminescence in primary AML cells, RGX946 ( A ), RGX694 ( B ), RGX702 ( C ), and RGX470 ( D ) treated with the indicated concentrations of RGX-019-MMAE or the monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). E Representative figures of colony-forming units for normal peripheral blood mononuclear cells in response to DMSO and indicated concentrations of RGX-019-MMAE and RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test) * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001

Article Snippet: Mouse IgG1/kappa light chain MERTK-specific monoclonal antibodies were generated in mice by immunization with Fc-tagged human MERTK peptide (R&D Systems, Minneapolis, MN) USA).

Techniques: Activity Assay, Expressing